Moderna, Inc.

We are mRNA. And mRNA is us.

Every day, we come together to create the blueprints needed to fight and eradicate diseases, and to help people live healthier lives. And the world has witnessed the powerful benefits of our platform technology.

With mRNA technology, we are completely reimagining how medicines are created and delivered. And in the process, we’re launching an entirely new industry, one fueled by deep care for our teams as well as for others.

Through the power of mRNA, we’re giving our people a platform to change medicine—and an opportunity to change the world.

Come with us as we pursue the uncharted reaches of possibility and make your mark on the future of medicine: modernatx.com/careers

  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
200 Technology Square
Cambridge, MA
Stock Symbol: MRNA
Stock Exchange: USNASDAQ GS

  • Featured Employer

Changing the future of medicine starts with our people. Across Moderna, our colleagues are working to make the impossible possible, and our goal is to support them every step of the way. Our workforce has grown significantly over the last few years as we have rapidly scaled to become a global commercial company. With more than 5,500 people around the world, we are focused on creating an environment that is rooted in a strong sense of belonging. Hear from our changemakers.

At Moderna, our changemakers are actively building a better future, one innovation at a time. We recently asked Keke if she could create a six-word story about what being a changemaker meant to her.
We know that you will give us your all and we want to make sure that we’re doing the same for you and the people closest to you. We’re on this incredible journey of pushing past the possible together, which is why we provide paramount support for both you and your family.
NEWS
FDA
The FDA said that there had been concerns over the reduced effectiveness of the Moderna COVID-19 vaccine against symptomatic disease.
Teamed up with pharma giant GlaxoSmithKline, CureVac is now focusing on a more promising target – second-generation mRNA vaccines.
Although there are many effective and safe COVID-19 vaccines around the world, the preferred vaccine is the Pfizer-BioNTech vaccine. For that and more stories, read on.
As US vaccination rates have been hovering in the 50% of the population range for two months, President Biden hit the old dusty trail to push his vaccine mandate even more.
Moderna seeks to invalidate two patents of Arbutus Biopharma Corp. The company hopes to appeal a preemptive challenge to the patents upheld by the U.S. Patent Trial and Appeals Board.
Data from the Phase II CYPRESS study presented at the virtual IDWeek (Infectious Disease Week) 2021 showed that the vaccine candidate provided a robust response against the infection.
Johnson & Johnson is expected to ask the U.S. Food and Drug Administration to authorize a booster for its one-shot COVID-19 vaccine this week.
Marked by recent announcements of new manufacturing sites, headquarters and job creations, the life science industry continues to thrive despite the COVID-19 pandemic.
The Pfizer-BioNTech booster shot is now authorized for people over 18 and 65 who are immunocompromised, at high risk due to their work or living situation and front-line healthcare workers.
JOBS
  • 2025 Hotbed Maps - Genetown - Elite - Moderna.png
IN THE PRESS